N4 Pharma PLC Market Cap ($48.10K)
Market Cap & Net Worth: N4 Pharma PLC (N4P)
N4 Pharma PLC market cap. N4 Pharma PLC (LSE:N4P) has a market capitalization of $48.10K (GBX395.33 Million) as of November 3, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31683 globally and #1202 in its home market, demonstrating a -9.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying N4 Pharma PLC's stock price GBX0.48 by its total outstanding shares 832280349 (832.28 Million). Also see N4P cash flow metrics for how efficiently the company converts equity into cash flow.
N4 Pharma PLC Market Cap History (2015–2026)
N4 Pharma PLC market cap history from 2015 to 2026. Data shows change from $222.78K to $48.10K (-16.24% CAGR). Check N4 Pharma PLC (N4P) share price today for real-time trading data and today's change.
Index Memberships
N4 Pharma PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$998.29 Million | 0.00% | #409 of 722 |
Weight: N4 Pharma PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
N4 Pharma PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how N4 Pharma PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore N4 Pharma PLC (N4P) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.30x
N4 Pharma PLC's market cap is 7.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $506.32K | $1.16 Million | -$22.00K | 0.44x | N/A |
| 2017 | $1.03 Million | $109.91K | -$1.84 Million | 9.33x | N/A |
| 2018 | $946.82K | $72.83K | -$1.19 Million | 13.00x | N/A |
| 2023 | $86.07K | $1.95K | -$1.27 Million | 44.07x | N/A |
| 2024 | $53.16K | $7.28K | -$1.06 Million | 7.30x | N/A |
Competitor Companies of N4P by Market Capitalization
Companies near N4 Pharma PLC in the global market cap rankings as of November 3, 2026. Also see how large is N4 Pharma PLC's balance sheet for a full breakdown of the balance sheet.
Key companies related to N4 Pharma PLC by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of N4 Pharma PLC (2015–2026)
Market capitalization of N4 Pharma PLC from 2015 to today. Between 2015 and today, N4 Pharma PLC's market cap moved from $222.78K to $ 48.10K, with a yearly change of -16.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX48.10K | -9.52% |
| 2025 | GBX53.16K | 0.00% |
| 2024 | GBX53.16K | -38.24% |
| 2023 | GBX86.07K | -54.05% |
| 2022 | GBX187.34K | -59.78% |
| 2021 | GBX465.82K | -44.91% |
| 2020 | GBX845.56K | +203.64% |
| 2019 | GBX278.48K | -70.59% |
| 2018 | GBX946.82K | -7.65% |
| 2017 | GBX1.03 Million | +102.50% |
| 2016 | GBX506.32K | +127.27% |
| 2015 | GBX222.78K | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of N4 Pharma PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.10K USD |
| MoneyControl | $48.10K USD |
| MarketWatch | $48.10K USD |
| marketcap.company | $48.10K USD |
| Reuters | $48.10K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About N4 Pharma PLC
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequen… Read more